Closing the gap on drug‐induced liver injury
Marion Maurel, Jean Rosenbaum – 25 July 2012 – Drug‐induced liver injury (DILI) limits the development and application of many therapeutic compounds and presents major challenges to the pharmaceutical industry and clinical medicine. Acetaminophen‐containing compounds are among the most frequently prescribed drugs and are also the most common cause of DILI. Here we describe a pharmacological strategy that targets gap junction communication to prevent amplification of fulminant hepatic failure and acetaminophen‐induced hepatotoxicity.